Zonisamide Maintenance Dose
The recommended maintenance dose of zonisamide is 400 mg/day, with an effective range of 100-600 mg/day, though doses above 400 mg/day show minimal additional benefit. 1
Dosing Algorithm
Initial Titration
- Start at 100 mg daily for 2 weeks 1
- Increase to 200 mg/day for at least 2 weeks
- Further titrate to 300 mg/day, then 400 mg/day, maintaining each dose for at least 2 weeks to achieve steady state 1
Maintenance Dosing
- Target maintenance dose: 400 mg/day 1
- Effective range: 100-600 mg/day 1
- Can be administered once or twice daily (no difference in efficacy) 1
- May be taken with or without food 1
Evidence-Based Efficacy by Dose
The FDA label and clinical trials demonstrate clear dose-response relationships 1:
- 100 mg/day: 25% responder rate (≥50% seizure reduction)
- 200 mg/day: 25% responder rate
- 400 mg/day: 43-50% responder rate
- Above 400 mg/day: No significant additional benefit 1
Real-world data from the OZONE study (428 patients) confirms a median maintenance dose of 300 mg/day in clinical practice 2, though the FDA-approved target remains 400 mg/day.
Critical Titration Considerations
Allow up to 2 weeks at each dose level to reach steady state due to zonisamide's long half-life (27-46 hours depending on concurrent medications) 1. This is essential—rushing titration increases adverse events without improving efficacy.
Half-Life Variations
- With enzyme-inducing AEDs (phenytoin, carbamazepine, phenobarbital): 27-38 hours 1
- With non-enzyme-inducing AEDs (valproate): 46 hours 1
- Without enzyme inducers: ~60 hours 3
Special Populations
Renal or hepatic impairment: Use slower titration and more frequent monitoring, as zonisamide is both hepatically metabolized and renally excreted 1. The FDA label specifically cautions treating these patients with care.
Pediatric patients (6-17 years): Target dose is 8 mg/kg/day, initiated at 1 mg/kg/day and titrated over 8 weeks 4. This achieved a 50% responder rate in phase III trials.
Common Pitfalls to Avoid
Rapid titration: The most frequent adverse events (somnolence, dizziness, anorexia) occur more commonly at doses ≥300 mg/day 1. Slow titration minimizes these effects.
Exceeding 400 mg/day without justification: Evidence shows no meaningful increase in response above 400 mg/day 1, while adverse events increase.
Ignoring drug interactions: When adding or removing CYP3A4-inducing AEDs, zonisamide concentrations will change, requiring dose adjustment 1.
Overlooking carbonic anhydrase inhibitor interactions: Concurrent use with topiramate or acetazolamide increases metabolic acidosis and kidney stone risk 1.
Tolerability Profile
Discontinuation rates in controlled trials were only 10% at therapeutic doses 5, comparable to placebo. The most common adverse events are somnolence, dizziness, anorexia, and weight loss 5, 3. Real-world data shows somnolence in only 5.1% of patients 2, suggesting good tolerability when properly titrated.